https://www.selleckchem.com/pr....oducts/nvp-bsk805.ht
3%, and pulmonary embolus in 27.9%. Overall, 79.1% received immunomodulation with methylprednisolone for persistent maladaptive hyperinflammatory state. Vasopressors were used in 86%, and 44.2% received renal replacement therapy. Median duration on VV-ECMO was 13 days (interquartile range 8-2. 14 patients died (32.6%) and 29 survived (67.4%) to hospital discharge. Nonsurvivors had significantly higher d-dimer (38.2 9.5 mg·L , fibrinogen equivalent units; p=0.035) and creatinine (169 73 μmol·L ; p=0.022) at commencement of VV-ECMO.
Like
Comment
Share
